JP2020515578A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020515578A5 JP2020515578A5 JP2019553113A JP2019553113A JP2020515578A5 JP 2020515578 A5 JP2020515578 A5 JP 2020515578A5 JP 2019553113 A JP2019553113 A JP 2019553113A JP 2019553113 A JP2019553113 A JP 2019553113A JP 2020515578 A5 JP2020515578 A5 JP 2020515578A5
- Authority
- JP
- Japan
- Prior art keywords
- cancer
- pharmaceutically acceptable
- acceptable salt
- antibody
- drug conjugate
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 0 *N(C(CC1)=O)C1=O Chemical compound *N(C(CC1)=O)C1=O 0.000 description 4
- XJLIZVNBNOGQIZ-UHFFFAOYSA-N CC(C)(CCOC(C)(C)CCN(C(C=C1)=O)C1=O)C(NCCNC)=O Chemical compound CC(C)(CCOC(C)(C)CCN(C(C=C1)=O)C1=O)C(NCCNC)=O XJLIZVNBNOGQIZ-UHFFFAOYSA-N 0.000 description 1
- QXYUPYCLYVKFML-UHFFFAOYSA-N CC(C)NCCN(C(C(Br)=C1Br)=O)C1=O Chemical compound CC(C)NCCN(C(C(Br)=C1Br)=O)C1=O QXYUPYCLYVKFML-UHFFFAOYSA-N 0.000 description 1
- CEKBIZXSKXIHKR-QWRGUYRKSA-N CC(C)[C@@H](C(N[C@@H](CCCNC(N)=O)C(C)=O)=O)NC Chemical compound CC(C)[C@@H](C(N[C@@H](CCCNC(N)=O)C(C)=O)=O)NC CEKBIZXSKXIHKR-QWRGUYRKSA-N 0.000 description 1
- BYTQYJBXDFBAMS-UHFFFAOYSA-N CCN(C1OC1C(C)C1)C1=O Chemical compound CCN(C1OC1C(C)C1)C1=O BYTQYJBXDFBAMS-UHFFFAOYSA-N 0.000 description 1
- FEPCRJPVYFSZFH-UHFFFAOYSA-N CNCCN(C(C=C1)=O)C1=O Chemical compound CNCCN(C(C=C1)=O)C1=O FEPCRJPVYFSZFH-UHFFFAOYSA-N 0.000 description 1
- ZYPSDIUSNSIUEG-UHFFFAOYSA-N CNCCN(C(CC1=C)=O)C1=O Chemical compound CNCCN(C(CC1=C)=O)C1=O ZYPSDIUSNSIUEG-UHFFFAOYSA-N 0.000 description 1
- LDNWXFQQLQTQKU-UHFFFAOYSA-N CNCCNC(C(CC(O)=O)=C)=O Chemical compound CNCCNC(C(CC(O)=O)=C)=O LDNWXFQQLQTQKU-UHFFFAOYSA-N 0.000 description 1
- BNUHAJGCKIQFGE-UHFFFAOYSA-N COc(cc1)ccc1[N+]([O-])=O Chemical compound COc(cc1)ccc1[N+]([O-])=O BNUHAJGCKIQFGE-UHFFFAOYSA-N 0.000 description 1
- CVYZVNVPQRKDLW-UHFFFAOYSA-N COc(ccc([N+]([O-])=O)c1)c1[N+]([O-])=O Chemical compound COc(ccc([N+]([O-])=O)c1)c1[N+]([O-])=O CVYZVNVPQRKDLW-UHFFFAOYSA-N 0.000 description 1
- HNKJADCVZUBCPG-UHFFFAOYSA-N CSc1ccccc1 Chemical compound CSc1ccccc1 HNKJADCVZUBCPG-UHFFFAOYSA-N 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP17163065.0 | 2017-03-27 | ||
| EP17163065.0A EP3381474A1 (en) | 2017-03-27 | 2017-03-27 | Histone deacetylase inhibitors-based antibody drug conjugates (adcs) and use in therapy |
| PCT/EP2018/057744 WO2018178060A1 (en) | 2017-03-27 | 2018-03-27 | HDAC INHIBITORS-BASED ANTIBODY DRUG CONJUGATES (ADCs) AND USE IN THERAPY |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2020515578A JP2020515578A (ja) | 2020-05-28 |
| JP2020515578A5 true JP2020515578A5 (https=) | 2021-02-12 |
Family
ID=58448395
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019553113A Pending JP2020515578A (ja) | 2017-03-27 | 2018-03-27 | Ｈｄａｃ阻害剤系抗体薬物コンジュゲート（ａｄｃ）及び治療における使用 |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US20210128740A1 (https=) |
| EP (2) | EP3381474A1 (https=) |
| JP (1) | JP2020515578A (https=) |
| KR (1) | KR20190126824A (https=) |
| CN (1) | CN110475572A (https=) |
| AU (1) | AU2018241840A1 (https=) |
| BR (1) | BR112019013449A2 (https=) |
| CA (1) | CA3047359A1 (https=) |
| EA (1) | EA201991985A1 (https=) |
| IL (1) | IL268821A (https=) |
| MX (1) | MX2019011492A (https=) |
| SG (2) | SG10202109654SA (https=) |
| TN (1) | TN2019000187A1 (https=) |
| UA (1) | UA125311C2 (https=) |
| WO (1) | WO2018178060A1 (https=) |
Families Citing this family (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3930746A4 (en) | 2019-02-25 | 2023-03-15 | Emory University | CHIMERA COMPOUNDS AND METHODS FOR MANAGEMENT OF NEUROLOGICAL DISORDERS OR CONDITIONS |
| AU2020380333A1 (en) * | 2019-11-06 | 2022-04-07 | Dana-Farber Cancer Institute, Inc. | Selective histone deacetylase (HDAC) degraders and methods of use thereof |
| EP4183781A4 (en) * | 2020-07-20 | 2024-01-03 | Jiangsu Hengrui Pharmaceuticals Co., Ltd. | Sulfur-containing isoindoline derivative, and preparation method therefor and medical use thereof |
| CN112430229B (zh) * | 2020-11-24 | 2023-03-21 | 福建医科大学 | 一种靶向降解parp蛋白的化合物及其制备方法与应用 |
| CN113292465B (zh) * | 2021-06-17 | 2022-11-08 | 贵州医科大学 | 一种半胱氨酸衍生物及其合成方法、应用 |
| WO2023059581A1 (en) * | 2021-10-04 | 2023-04-13 | Halda Therapeutics Opco, Inc. | Heterobifunctional compounds and their use in treating disease |
| WO2023061405A1 (zh) * | 2021-10-12 | 2023-04-20 | 成都科岭源医药技术有限公司 | 一种高稳定性的靶向接头-药物偶联物 |
| EP4631956A1 (en) * | 2022-11-25 | 2025-10-15 | Chengdu Chipscreen Newway Biosciences Co., Ltd. | Linker, linker-containing antibody drug conjugate, and preparation method therefor and use thereof |
| AU2024265078A1 (en) | 2023-05-04 | 2025-12-11 | Revolution Medicines, Inc. | Combination therapy for a ras related disease or disorder |
| CN116554079B (zh) * | 2023-07-11 | 2023-11-10 | 南京市鸿舜医药科技有限公司 | 一种组蛋白去乙酰化酶抑制剂及用途 |
| IL326136A (en) | 2023-08-07 | 2026-03-01 | Revolution Medicines Inc | RMC-6291 for use in the treatment of a disease or disorder associated with the RAS protein |
| US20250154171A1 (en) | 2023-10-12 | 2025-05-15 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2025171296A1 (en) | 2024-02-09 | 2025-08-14 | Revolution Medicines, Inc. | Ras inhibitors |
| TW202543650A (zh) | 2024-03-08 | 2025-11-16 | 美商海爾達醫療運營公司 | 異雙官能化合物及其在治療疾病中之用途 |
| WO2025228384A1 (en) * | 2024-04-30 | 2025-11-06 | Hutchmed Limited | Antibody-drug conjugates and use thereof |
| WO2025240847A1 (en) | 2024-05-17 | 2025-11-20 | Revolution Medicines, Inc. | Ras inhibitors |
| US20250375445A1 (en) | 2024-06-07 | 2025-12-11 | Revolution Medicines, Inc. | Methods of treating a ras protein-related disease or disorder |
| WO2025265060A1 (en) | 2024-06-21 | 2025-12-26 | Revolution Medicines, Inc. | Therapeutic compositions and methods for managing treatment-related effects |
| WO2026006747A1 (en) | 2024-06-28 | 2026-01-02 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026015796A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026015801A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026015825A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Use of ras inhibitor for treating pancreatic cancer |
| WO2026015790A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026050446A1 (en) | 2024-08-29 | 2026-03-05 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026072904A2 (en) | 2024-09-26 | 2026-04-02 | Revolution Medicines, Inc. | Compositions and methods for treating lung cancer |
| CN121401440A (zh) * | 2025-10-21 | 2026-01-27 | 北京晟日昭阳生物科技有限公司 | 一种靶向治疗胰腺癌的抗体偶联物及其制备方法和应用 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN109045307A (zh) * | 2004-06-01 | 2018-12-21 | 健泰科生物技术公司 | 抗体-药物偶联物和方法 |
| JP5377968B2 (ja) * | 2005-11-10 | 2013-12-25 | トポターゲット ユーケー リミテッド | 癌治療のために単独で用いるまたは化学療法薬と併用するヒストンデアセチラーゼ（ｈｄａｃ）阻害剤 |
| EP2276506A4 (en) * | 2008-04-30 | 2014-05-07 | Immunogen Inc | EFFICIENT CONJUGATES AND HYDROPHILIC BINDER |
| GB201309807D0 (en) * | 2013-05-31 | 2013-07-17 | Pharma Mar Sau | Antibody drug conjugates |
| US20170319709A1 (en) * | 2013-07-05 | 2017-11-09 | Formation Biologics Inc. | Egfr antibody conjugates |
| LT3129406T (lt) * | 2014-04-11 | 2019-04-10 | Medimmune, Llc | Konjuguoti junginiai, apimantys inžineriniu būdu sukonstruotus cisteino antikūnus |
-
2017
- 2017-03-27 EP EP17163065.0A patent/EP3381474A1/en not_active Withdrawn
-
2018
- 2018-03-27 EA EA201991985A patent/EA201991985A1/ru unknown
- 2018-03-27 JP JP2019553113A patent/JP2020515578A/ja active Pending
- 2018-03-27 TN TNP/2019/000187A patent/TN2019000187A1/en unknown
- 2018-03-27 SG SG10202109654S patent/SG10202109654SA/en unknown
- 2018-03-27 CA CA3047359A patent/CA3047359A1/en active Pending
- 2018-03-27 US US16/492,355 patent/US20210128740A1/en not_active Abandoned
- 2018-03-27 MX MX2019011492A patent/MX2019011492A/es unknown
- 2018-03-27 UA UAA201909898A patent/UA125311C2/uk unknown
- 2018-03-27 CN CN201880022128.4A patent/CN110475572A/zh active Pending
- 2018-03-27 SG SG11201906543RA patent/SG11201906543RA/en unknown
- 2018-03-27 KR KR1020197028286A patent/KR20190126824A/ko not_active Withdrawn
- 2018-03-27 WO PCT/EP2018/057744 patent/WO2018178060A1/en not_active Ceased
- 2018-03-27 BR BR112019013449A patent/BR112019013449A2/pt not_active IP Right Cessation
- 2018-03-27 AU AU2018241840A patent/AU2018241840A1/en not_active Abandoned
- 2018-03-27 EP EP18712246.0A patent/EP3600444A1/en not_active Withdrawn
-
2019
- 2019-08-21 IL IL26882119A patent/IL268821A/en unknown